CoChat

Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction

Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., Clayton, A. H. · 2015 · The Journal of Sexual Medicine
Cited by 116

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Abstract

Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs), and does not resolve in most patients. Vortioxetine, an antidepressant with a multimodal mechanism of action, has shown low rates of sexual dysfunction in previous major depressive disorder (MDD) trials. Aim: This study compared the effects of vortioxetine and escitalopram on sexual functioning in adults with well-treated MDD experiencing treatment-emergent sexual dysfunction (TESD). Methods: Participants treated with, and responding to, citalopram, paroxetine, or sertraline were randomized to switch to either vortioxetine (10/20 mg; n = 225) or escitalopram (10/20 mg; n = 222) for 8 weeks. Sexual function was assessed using the Changes in Sexual Functioning Questionnaire Short Form (CSFQ-14), and antidepressant efficacy was assessed using the Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impressions (CGI) scale, and Profile of Mood States brief form (POMS-brief). Safety and tolerability were also assessed. Main Outcome Measures: The primary endpoint was change from baseline in the CSFQ-14 total score after 8 weeks of treatment. The MADRS, CGI, and POMS-brief were used to assess antidepressant efficacy. Safety was assessed via adverse events, vital signs, electrocardiograms, laboratory values, weight, and physical examination findings. Results: Vortioxetine showed significantly greater improvements in CSFQ-14 total score (8.8 ± 0.64, mean ± standard error) vs. escitalopram (6.6 ± 0.64; P = 0.013). Benefits vs. escitalopram were significant on four of five dimensions and all three phases of sexual functioning assessed by the CSFQ-14 (P < 0.05). Antidepressant efficacy continued in both groups, with similar, but slight, improvements in MADRS and CGI scores. Vortioxetine and escitalopram had similar clinical efficacy profiles in this study, with safety profiles similar to previous trials. Nausea (n = 9, 4.0%) was the most common treatment-emergent adverse event leading to discontinuation of vortioxetine. Conclusion: Switching antidepressant therapy to vortioxetine may be beneficial for patients experiencing sexual dysfunction during antidepressant therapy with SSRIs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jsm.12980

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Research works printed but not linked: 29

  1. Clayton, 2006, Major depressive disorder, antidepressants, and sexual dysfunction, J Clin Psychiatry, 67, 33
  2. Corona, 2009, Selective serotonin reuptake inhibitor-induced sexual dysfunction, J Sex Med, 6, 1259, 10.1111/j.1743-6109.2009.01248.x · DOI
  3. Clayton, 2007, Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder, J Sex Med, 4, 917, 10.1111/j.1743-6109.2007.00520.x · DOI · Paper page
  4. Delgado, 2005, Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder, J Clin Psychiatry, 66, 686, 10.4088/JCP.v66n0603 · DOI · Paper page
  5. Montejo, 2001, Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction, J Clin Psychiatry, 62, 10
  6. Rosen, 1999, Effects of SSRIs on sexual function: A critical review, J Clin Psychopharmacol, 19, 67, 10.1097/00004714-199902000-00013 · DOI · Paper page
  7. Williams, 2010, Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: Replication in a cross-sectional patient survey, J Psychopharmacol, 24, 489, 10.1177/0269881109102779 · DOI
  8. Ashton, 1998, Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction, J Sex Marital Ther, 24, 191, 10.1080/00926239808404932 · DOI
  9. Liang, 2012, 5-HT2A receptor-1438 G/A polymorphism and serotonergic antidepressant-induced sexual dysfunction in male patients with major depressive disorder: A prospective exploratory study, J Sex Med, 9, 2009, 10.1111/j.1743-6109.2012.02769.x · DOI
  10. Sidi, 2012, Female sexual dysfunction in patients treated with antidepressant-comparison between escitalopram and fluoxetine, J Sex Med, 9, 1392, 10.1111/j.1743-6109.2011.02256.x · DOI
  11. Clayton, 2014, Sexual dysfunction associated with major depressive disorder and antidepressant treatment, Expert Opin Drug Saf, 13, 1361, 10.1517/14740338.2014.951324 · DOI · Paper page
  12. Taylor, 2013, Strategies for managing sexual dysfunction induced by antidepressant medication, Cochrane Database Syst Rev
  13. Higgins, 2010, Antidepressant-associated sexual dysfunction: Impact, effects, and treatment, Drug Healthc Patient Saf, 2, 141, 10.2147/DHPS.S7634 · DOI · Paper page
  14. Rizvi, 2013, Management strategies for SSRI-induced sexual dysfunction, J Psychiatry Neurosci, 38, E27, 10.1503/jpn.130076 · DOI
  15. Clayton, 2014, Antidepressants and sexual dysfunction: Mechanisms and clinical implications, Postgrad Med, 126, 91, 10.3810/pgm.2014.03.2744 · DOI
  16. Baldwin, 2012, A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD), Eur Neuropsychopharmacol, 22, 482, 10.1016/j.euroneuro.2011.11.008 · DOI
  17. Mahableshwarkar, 2013, A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder, Curr Med Res Opin, 29, 217, 10.1185/03007995.2012.761600 · DOI · Paper page
  18. Guy, 1976, Clinical Global Impressions (028-CGI), 217
  19. Clayton, 1997, Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ), Psychopharmacol Bull, 33, 747
  20. Clayton, 1997, The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity, Psychopharmacol Bull, 33, 731
  21. Montgomery, 1979, A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, 382, 10.1192/bjp.134.4.382 · DOI · Paper page
  22. Thase, 2006, A double-blind comparison between bupropion XL and venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability, J Clin Psychopharmacol, 26, 482, 10.1097/01.jcp.0000239790.83707.ab · DOI · Paper page
  23. Jacobsen, 2014, The effect of vortioxetine on sexual dysfunction during the treatment of adults with major depressive disorder (MDD) or generalized anxiety disorder (GAD) [abstract], Poster presented at 54th Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP/NCDEU), June 16–19
  24. Lepola, 2003, Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care, Int Clin Psychopharmacol, 18, 211, 10.1097/01.yic.0000074988.54339.7c · DOI · Paper page
  25. Wade, 2002, Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care, Int Clin Psychopharmacol, 17, 95, 10.1097/00004850-200205000-00001 · DOI · Paper page
  26. Bech, 2004, Escitalopram dose-response revisited: An alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression, Int J Neuropsychopharmacol, 7, 283, 10.1017/S1461145704004365 · DOI · Paper page
  27. Kreilgaard, 2008, Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice, Br J Pharmacol, 155, 276, 10.1038/bjp.2008.243 · DOI · Paper page
  28. Baldwin, 2006, Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine, J Psychopharmacol, 20, 91, 10.1177/0269881105056666 · DOI · Paper page
  29. Baldwin, 2013, Reduced treatment-emergent sexual dysfunction as a potential target in the development of new antidepressants, Depress Res Treat, 2013, 256841

Cited by

Metadata

Authors
Jacobsen, P. L., Mahableshwarkar, A. R., Chen, Y., Chrones, L., & Clayton, A. H.
Venue
The Journal of Sexual Medicine
Published
2015-10-01
Volume
12
Issue
10
Pages
2036-2048
ISSN
  • 1743-6095 (ISSN-L)
  • 1743-6109
OpenAlex
W1917104769
Cited by
116
References
19
FWCI
7.96
Type
journal article
Language
en
Open access
closed
Funders
  • H. Lundbeck A/S
  • Takeda Pharmaceutical Company Ltd.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.